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Abstract 
 
 
 
 
 
This  paper  discusses  the  controversy  around  the  potentially  imminent 
commercialization of the first genetically engineered animal for human food 
consumption in the United States. The industrialization of commercial fishing 
in the wake of growing demand has led to a rapid decline in wild fish stocks. 
Over the last 50 years, modern aquaculture has developed into an important 
industry, to the point that it now supplies nearly half of all the fish humans 
consume.  Yet  modern  aquaculture,  including  its  two  main  commercial 
products,  shrimp  and  salmon,  is  also  associated  with  significant 
environmental problems, as well as other health, social and economic ones. 
Partially  in  response  to  these  problems,  several  companies  and  countries 
have  turned  to  genetic  engineering  as  a  possible  means  to  improve  the 
efficiency of fish farming. Leading this effort, AquaBounty Technologies, a 
Massachusetts  company  with  operations  in  both  Canada  and  Panama,  is 
attempting to commercialize all-female infertile fish for human consumption. 
Using recombinant DNA (rDNA) technology, AquaBounty created an Atlantic 
salmon that grows twice as fast as its non-engineered counterpart. By summer 
2010,  AquaBounty  announced  that  is  had  successfully  fulfilled  all  the 
requirements  necessary  under  the  FDA’s  New  Animal  Drug  Application 
(NADA),  the  agency’s  current  framework  for  regulating  genetically 
engineered  animals  with  hereditary  rDNA  constructs.  Yet  despite  what 
seemed to be the FDA’s inclination to allow AquaBounty to commercialize the 
AquAdvantage salmon soon after a public hearing held in September 2010, 
the  application  continues  to  stir  significant  controversy  and  remains 
unresolved. The FDA’s cautious response is perhaps unsurprising given the 
significance  of  this  decision  for  other  pending  commercializations  of 
genetically engineered animals and the criticism suggesting the unsuitability 
of the NADA framework to authorize such novel food.   - 1 -   
1  Background on Fisheries and Aquaculture 
1.1  The State of the World’s Fisheries 
1.1.1  In General 
 
The industrialization of fishing in the 1950s and 1960s lead to a major increase in 
global fish catches, leading to widespread over-fishing and the collapse of many fish 
stocks.
1 According to the United Nations Food and Agricultural Organization’s (FAO) 
most recent assessment of worldwide fish stocks, in 2008, over one third of worldwide 
fish stocks were over exploited or depleted, a nearly three fold increase over the past 35 
years. Just over half of fish stocks were classified as fully exploited, meaning that they 
were at or close to their maximum sustainable limit of exploitation.
2 As of 2008, total 
world fish production was 142 million tons, of which 100 million tons were marine fish. 
Nearly 80 million tons of marine fish were captured, while the remaining 20 million was 
produced from aquaculture.
3 Out of the 142 million tons produced both from fresh water 
and marine sources, approximately 115 million tons was used for human food, with the 
remaining balance used for other products, in particular fishmeal and fish oil.
4 
The  increase  in  fully  exploited  or  over-exploited  fish  stocks  parallels  a  slow 
decline of marine captures over the past decade.
5 While environmental conditions have 
also  contributed  in  some  cases  to  the  decline  of  fish  stocks,  over-fishing  is  widely 
                                                 
1 MICHELLE ALLSOPP ET AL., STATE OF THE WORLD’S OCEANS 33 (Springer Science + Business Media B.V. 
2009). 
2 FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS, THE STATE OF THE WORLD FISHERIES 
AND AQUACULTURE 2010 35 (Food and Agriculture Organization of the United Nations 2010), available at 
http://www.fao.org/docrep/013/i1820e/i1820e.pdf. 
3 Id. at 3. 
4 Id. at 3. 
5 Id. at 4.   - 2 -   
recognized as the main cause of the problem.
6 Particularly notable is the severe decline in 
predatory  fish,  including  salmon.  One  study  suggests  that  predatory  fish  stocks  have 
declined to just 11% of the levels they were at one hundred years ago.
7 The decline in 
predatory fish is concerning because it is indicative of the amount of pressure that human 
exploitation is imposing on the ocean. The decline in the mean trophic level
8 of fishery 
catches
9 implies that a decline in large predatory fish at the top of the food chain is 
forcing fishermen to switch to fishing smaller and younger fish lower down in the food 
chain.
10  
Although not devoid of problems of its own, aquaculture has been increasingly 
viewed as a solution to the depletion of the world’s fisheries. The increase in aquaculture 
production is such that is has offset the loss in natural fisheries production to the point 
that fish availability per capita has increased from 16.2 kg per person in 2004 to 17.2 kg 
per person in 2009.
11 Aquaculture already supplies 55 million tons out of the total 118 
million tons of fish consumed annually by humans, and a further increase in aquaculture 
production may help reduce the pressures on wild fish stocks.
12 
                                                 
6 ALLSOPP ET AL. supra note 1 at 35. 
7 Villy Christensen et al., Hundred-year Decline of North Atlantic Predatory Fishes, 4 FISH AND FISHERIES 
1 (2003), available at http://www2.fisheries.com/archive/members/dpauly/journalarticles/2003/ 
hundredyeardeclinenorthatlanticfishes.pdf. 
8 The trophic level of an animal describes the position it holds within the food web. In marine settings, the 
trophic level indicates how far up in the food web a particular fish relative to algae, which are situated at 
the bottom of the food web and are given a trophic level of 1. Zooplankton that consumes algae is thus 
assigned a trophic level of 2, smaller fish that consume the zooplankton are assigned a trophic level of 3, 
and so forth. Large predatory fish are usually assigned a trophic level of 3.5 to 4.5. See Daniel Pauly and 
Reg Watson, Background and Interpretation of the ‘Marine Trophic Index’ as a Measure of Biodiversity, 
28 PHIL. TRANS. R. SOC. B 415 (2005). 
9 Ransom A. Myers & Boris Worm, Rapid Worldwide Depletion of Predatory Fish Communities, 423 
NATURE 280 (2003). 
10 D. Pauly and R. Watson supra note 8. 
11 Id. at 3. 
12 STATE OF THE WORLD FISHERIES AND AQUACULTURE 2010 supra note 2 at 3.   - 3 -   
1.1.2  Wild Salmon 
 
Wild salmon used to be plentiful. In fact, for many years, salmon was considered 
a poor man’s fish, and fed often enough in prisons to cause prisoner revolts in both in 
Europe and the New World.
13 However, after Danish and Faroe Island fishermen in the 
1950s  found  the  areas  off  Greenland  where  Atlantic  salmon  congregated  and  started 
fishing them in large quantities, and the Norwegians and the Swedes joined them in the 
1960s,  wild  Atlantic  salmon  quickly  went  into  permanent  decline.
14  By  contrast,  the 
Pacific species of salmon found in supermarkets today are still for the most part wild.
15 
However, diminished salmon runs across the Pacific coast of North America have left 
their viability in question.
16 For both Atlantic and Pacific salmon, excessive damming of 
salmon run rivers, in addition to over-fishing, are thought to be the cause of the declining 
wild stocks.
17 As a result, both fish are currently listed as endangered
18 and essentially all 
Atlantic salmon in supermarkets today is farmed.
19  
1.2  The State of Aquaculture 
 
Aquaculture is the fastest growing animal food sector in the world.
20 Species at the 
low end of the food chain such as shellfish, herbivorous fish and omnivorous fish are the 
                                                 
13 PAUL GREENBERG, FOUR FISH – THE FUTURE OF THE LAST WILD FOOD 26 (The Penguin Press 2010).  
14 Id. at 19. 
15 Id. 
16 California closed its salmon fishery completely for the first time in history in 2008 and the Columbia 
River now hosts less than a tenth of its historical run. GREENBERG supra note 12 at 20. 
17 Id. at 18. 
18 The Chinook salmon is only partially listed as endangered or threatened in its California and Washington 
state ranges. See Species Profile, Chinook Salmon (Oncorhynchus Tshawytscha), U.S. Fish and Wildlife 
Service, http://ecos.fws.gov/speciesProfile/profile/speciesProfile.action?spcode=E06D (last visited May 10, 
2011). Species Profile, Atlantic Salmon (Salmo Salar), U.S. Fish and Wildlife Service, 
http://ecos.fws.gov/speciesProfile/profile/speciesProfile.action?spcode=E07L (last visited May 10, 2011). 
19 GREENBERG supra note 13 at 18. 
20 ALLSOPP ET AL. supra note 1 at 85.   - 4 -   
most common, but aquaculture also plays an important role in the supply of carnivorous 
species like shrimp and salmon.
21  
Today’s aquaculture is conducted in two main settings. Freshwater aquaculture 
takes place in both naturally and artificially created ponds, often on agricultural land 
areas. Marine aquaculture takes place either in ponds built along the coast and filed with 
seawater, or more often in cages or net pens directly placed in coastal waters. Land-based 
systems can either encompass raceway systems, where water naturally flows through the 
fish farming operation, or re-circulating systems, in which fish are held in tanks and 
water is usually treated and re-circulated. Different levels of rearing intensity exist. At the 
most extensive level, fish are left to fend for themselves by feeding off naturally available 
food, while at the most intensive level, all of the required food, as well as pest and 
disease control drugs, are provided by the fish farmers to the fish.
22 
While growing both aquatic plants and animals has been practiced for over 4,000 
years, notably in Asia,
23 modern aquaculture is a recent phenomenon. Since its modern 
origins in the second half of the previous century, the pace of development has been 
staggering. Compared to the domestication of farm animals, the domestication of fish has 
been described as haven taking place “overnight.”
24 Equipment used to hold and rear fish 
has  evolved  significantly,  as  has  a  greater  understanding  of  fish  genetics  and 
reproduction.
25 Both of these have led to dramatic increases in productivity. For example, 
to enhance growth rates and ensure that fish are larger at the time they are harvested for 
                                                 
21 Id. 
22 ALLSOPP ET AL. supra note 1 at 89. 
23 GREENBERG supra note 13 at 69 – 70. 
24 William Howarth, Global Challenges in the Regulation of Aquaculture, in AQUACULTURE LAW AND 
POLICY: TOWARDS PRINCIPLED ACCESS AND OPERATIONS 13, 15 (David L. VanderZwaag and Gloria Chao 
eds., Routledge 2006). 
25 Greenberg supra note 13 at 81 – 125 provides a detailed discussion of the origins of sea bass farming, a 
fish with a particularly fickle reproduction cycle that doesn’t lend itself easily to domestication.   - 5 -   
processing, modern aquaculture often resorts to making fish sterile.
26 It is also used as 
part of modern aquaculture containment strategies to ensure that farmed fish that escape 
ocean  cages  and  pens  cannot  mate  with  wild  specimens.
27  Creating  sterile  fish  is 
relatively  simple.  To  do  so,  farmed  fish  eggs  are  subject  to  heat  or  pressure  shocks 
shortly  after  fertilization,  causing  them  to  retain  an  extra  set  of  chromosomes.  The 
resulting fish, termed “triploid,” end up with three sets of chromosomes as opposed to the 
normal two.
28  These fish fail to develop normal sexual characteristics and the female are 
sterile.  
In general, modern aquaculture has tended to choose the fish it raises and the 
production  methods  it  uses  based  on  consumer  demands  rather  than  on  principles  of 
sustainability.  The  expansion  of  aquaculture  has  been  associated  with  a  host  of 
environmental,  social,  economic,  health  and  ethical  issues.
29  Aquaculture’s 
environmental problems include the eutrophication and stimulation of unwanted algal 
blooms that result from the release of uneaten food pellets, dead fish and fish feces. In the 
case of ocean-based cage aquaculture, these releases occur directly into the surrounding 
ocean in which cages are located. As this waste decomposes, it releases both organic and 
inorganic nutrients, as well as nutrients that then stimulate algae growth. In nutrient-rich 
waters, as algae bloom and waste decompose, they deplete the waters’ oxygen content 
and result in oceanic dead zones.
30 Farmed fish also carry diseases and parasites that are 
transferable to wild fish stocks with potentially devastating effects. Evidence shows that 
                                                 
26 See G. Hulata, Genetic Manipulations in Aquaculture: A Review of Stock Improvement by Classical and 
Modern Technologies, 11 GENETICA 155, 161 – 162 (2001). 
27 Id. 
28 Id. 
29 See David L. VanderZwaag, Introduction – Aquaculture Law and Policy: Struggling in the Wake of the 
Blue Revolution, in AQUACULTURE LAW AND POLICY: TOWARDS PRINCIPLED ACCESS AND OPERATIONS 1, 
1 (David L. VanderZwaag and Gloria Chao eds., Routledge 2006). 
30 ALLSOPP ET AL. supra note 1 at 97 – 98.   - 6 -   
the prevalence of such diseases and parasites has increased in wild stock as a result of 
farmed fish escaping from their holding pens and transferring them directly to wild stock. 
Transfer also happens when high concentrations of infested farmed fish are held in waters 
that also serve as wild fish habitats.
31 Finally, the escape and potentially interbreeding of 
farmed fish with wild ones is a major concern.
32 Social and economic issues arise from 
the impact aquaculture is having on traditional fisheries, how access is granted to optimal 
fish farming sites, the highly concentrated state of the aquaculture industry and questions 
about working conditions and labor practices employed in the industry.
33 Health issues 
arise mostly from the higher concentrations of PCBs typically found in farmed fish and 
the potential impacts on humans of antibiotic use in aquaculture.
34 Finally, whether or not 
fish should be farmed, but more significantly whether or not fish should be genetically 
manipulated to grow faster, are core ethical questions associated with aquaculture.
35 
1.2.1  Salmon Aquaculture 
 
Salmon  domestication  started  in  Norway  in  the  early  1960s.  Salmon  proved 
particularly  adaptable  to  growth  in  captivity,  because,  contrarily  to  other  farmed 
predatory fish that depend on the presence of specific microscope organisms in their first 
larvae phases of life, salmon hatch out of large and nutrient rich eggs off which they live 
for the first few weeks of their lives.
36 From there, young salmon can relatively easily be 
transitioned over to eating chopped-up pieces of fish. By maintaining salmon in floating 
ocean cages, feeding them regularly, and keeping them safe by predators, early salmon 
                                                 
31 Id. at 100. 
32 Id. 
33 VanderZwaag supra note 29 at 1. 
34 Id. at 1 – 2. 
35 Id. at 2. 
36 GREENBERG supra note 13 at 40.   - 7 -   
farmers quickly realized that they had reversed the natural selection process that causes a 
99%  mortality  of  salmon  in  their  early  phases  of  life.
37  Combined  with  the  rapidly 
declining availability of naturally fished salmon, there was a clear financial incentive to 
further improve the aquaculture process.
38  
  Initial salmon farming was conducted using wild fish. Innovative Norwegians fish 
farmers then proceeded to cross and re-cross Atlantic salmon strains from forty different 
rivers to develop a fish that grew faster. In just fourteen years, or the time of seven 
generations of salmon, Norwegian fish farmers were able to double the growth rate of 
salmon.
39 This ensured dominance of the nascent fish farming industry. Expansion to 
other cold-water, fjord rich coastal regions of Chile,
40 Nova Scotia and British Columbia 
soon followed. Today, salmon is the most traded aquaculture product after shrimp. One-
and-a-half million metric tons of farmed salmon are traded annually, almost all of which 
is Atlantic salmon.
41 In the US alone, the annual value of the salmon trade, 97% of which 
is imported, is worth $1.39 billion.
42 Norway remains the principal exporter, with the 
European Union as its main market.
 43 Chile is an also an important producer, exporting 
mostly to Japan and the United States.
44 
  Improved  farming  techniques  ensure  that  fresh  salmon  is  now  available  year 
round, as opposed to seasonal wild catches. Farming has also resulted in a significant 
                                                 
37 Id. 
38 Id. 
39 Id. at 39. 
40 Interestingly enough, before the expansion of salmon farming industry to Chile, there was no salmon 
south of the equator since it acts as a thermal barrier that wild salmon, which require cold water, cannot 
cross. Id. at 43. 
41 Jeffrey L. Fox, Transgenic Salmon Inches Toward Finish Line, 29 NATURE 1141, 1141 (2010). 
42 Molly Peterson, This Genetically Altered Salmon is No Fish Story, 4197 BLOOMBERG BUSINESSWEEK 21 
(2010.) 
43 Ted L. McDorman and Torsten Strom, Aquaculture and the Multilateral Trade Regime: Issues of 
Seafood Safety, Labeling and the Environment, in AQUACULTURE LAW AND POLICY: TOWARDS PRINCIPLED 
ACCESS AND OPERATIONS 355, 355 (David L. VanderZwaag and Gloria Chao eds., Routledge 2006). 
44 Id.   - 8 -   
drop in the relative price of salmon, to a point that it is a relatively common offering in 
many  developed  country  diets.  The  increase  in  salmon  demand  is  also  driven  by 
consumer awareness about the health benefits of consuming omega-3 fatty acids. Omega-
3 fatty acids are commonly found in cold-water fish like salmon as they allow these fish 
to maintain pliable cell membranes in frigid waters. These fatty acids have the same 
effect  on  human  vascular  tissue  when  consumed  by  humans.
45  A  study  by  Harvard 
Medical School even suggests that the benefits of farmed salmon-derived omega-3 acids 
offsets  the  increased  exposure  to  PCB  poisoning  that  is  also  commonly  said  to  be 
associated with eating farmed salmon.
46 
  However,  salmon  farming  is  also  the  source  of  many  concerns.  First,  over  a 
million domesticated salmon escape into the wild annually. Opponents of salmon farming 
fear that tamed salmon risk displacing wild fish because they feed more aggressively and 
thus out-compete wild stocks
47 only to be later unable to reproduce as a result of having 
lost the traits essential to successfully spawn upriver in the wild.
48 Alternatively, there is 
the risk that farmed salmon, genetically modified or simply selectively bred, may actually 
breed with wild salmon and disrupt the natural gene pool. This so-called “Trojan gene” 
effect is driven by the ability of farmed salmon to reproduce much more effectively as a 
result of more aggressive feeding behaviors, but with the subsequent detrimental effect of 
                                                 
45 GREENBERG supra note 13 at 54. 
46 See Dariush Mozaffarian and Eric B. Rimm, Fish Intake, Contaminants, and Human Health: Evaluating 
the Risks and the Benefits, 296 J. OF AM. MED. ASS’N 1885 (2006). 
47 Several studies have shown that growth-enhanced tilapia and coho salmon eat nearly three times as much 
as their natural counterparts under laboratory conditions. Whether or not this would hold true in the wild is 
unclear. Studies by AquaBounty technologies suggest that the genetically engineered salmon are less likely 
to be careful about avoiding predators in their attempts to forage large amounts of food, and also exhibit 
poorer camouflage, suggesting that their ability to survive in the wild would be diminished. While this may 
suggest that escaped genetically modified salmon are less likely to successfully survive long enough to 
breed, should they however succeed in doing so, they could transfer unfavorable survival genes to wild 
salmon stocks. See Tony Reichhardt, Will Souped Up Salmon Sink or Swim?, 406 NATURE, 11, 12 (2000). 
48 GREENBERG supra note 13 at 44.   - 9 -   
producing future generations of crossbred offspring that are unable to reproduce because 
they do not possess the essential genes to thrive in the wild and the instinct to spawn 
upriver.
49  A  separate  concern  particular  to  farming  salmon  is  that  it  requires  large 
amounts of food, a major share of which consists of other smaller fish harvested from the 
wild.  Although  selective  breeding  has  improved  the  conversion  efficiency  from  the 
original six pounds of ground fish required to produce one pound of salmon to three,
50 the 
net loss of fish that results calls into question the sustainability of the process, particularly 
when the small fish in question serve as staple foods for developing nations.
51 
  Despite these concerns, the salmon industry is now a multi-billion dollar business 
and consumer demand is unlikely to abate. Demand for seafood is expected to double 
over the next thirty years and aquaculture is certain to play an important role in fulfilling 
this  demand.
52  Salmon  aquaculture  remains  a  relatively  young  industry  and  many 
advocate  for  reform  of  the  laws  and  practices  that  govern  it.
53  One  approach  under 
development in Atlantic Canada’s Bay of Fundy is referred to as Integrated Multitrophic 
Aquaculture (IMTA). Such a farming practice combines species that require feed with 
both species that extract inorganic nutrients and species that extract organic particulate 
matter. For example, to balance the polluting effect of feed-eating salmon, seaweed and 
mussels
54 can be used to extract both inorganic and organic pollutants respectively.
55 
Although IMTA is still in its infancy, it may provide the groundwork for the creation of a 
                                                 
49 Reichhardt supra note 47 at 11. 
50 GREENBERG supra note 13 at 44. 
51 ALLSOPP ET AL. supra note 1 at 105. 
52 See Erik Stokstad, Engineered Fish: Friend or Foe of the Environment, 297 SCIENCE 1798, 1798 (2002). 
53 See generally AQUACULTURE LAW AND POLICY: TOWARDS PRINCIPLED ACCESS AND OPERATIONS (David 
L. VanderZwaag and Gloria Chao eds., Routledge 2006) 
54 The presence of mussels in the waters surrounding salmon farms may also diminish the presence of 
infectious salmon anemia virus, an added benefit that is not overlooked by large salmon farming operations 
where the disease is rife. See GREENBERG supra note 13 at 72. 
55 GREENBERG supra note 13 at 69.   - 10 -   
fully closed feeding system whereby some of the species that feed on the waste generated 
by  salmon  would  then  be  used  to  feed  smaller  fish  that  are  themselves  fed  to  the 
salmon.
56  Such  a  system  may  also  address  the  problem  of  diminished  omega-3  acid 
content of farmed salmon when they are fed more grain-based diets in part to offset the 
higher PCB concentrations found in their wild fish feed. Because omega-3 acids can be 
duplicated by seaweed, in a closed feeding system, these acids would find their way into 
the smaller fish that feed on seaweed before being themselves fed to salmon.
57 
2  Overview of AquaBounty Technologies 
 
AquaBounty Technologies was incorporated in 1981 and is currently based in 
Waltham, Massachusetts.
58 Originally founded to pursue the commercial development of 
antifreeze protein applications in the medical, food and cosmetic field, researchers soon 
realized that the ability to turn the antifreeze gene on and off could also be applied to 
salmon’s growth hormone genes.
59 The company proceeded to create its first transgenic 
fish in 1989
60 and eventually acquired the license to enhanced fish growth technology 
from the University of Toronto and Memorial University of Newfoundland in 1996.
61 
While other companies and countries pursued research to enhance farmed salmon growth 
characteristics  using  similar  genetic  engineering  approaches,  many  abandoned  such 
efforts in the late 1990s, largely in response to consumer outcry. Notable, both Otter 
Ferry  Salmon  in  Scotland  and  New  Zealand  King  Salmon  Company  considered 
                                                 
56 ALLSOPP ET AL. supra note 1 at 110 - 112. 
57 GREENBERG supra note 13 at 72 – 73. 
58 AquaBounty Technologies, The Company, http://aquabounty.com/company/company-history-292.aspx 
(last visited April 25, 2011). 
59 Greenberg supra note 13 at 66.  
60 Fox supra note 41 at 1141. 
61 Id.   - 11 -   
developing  the  growth  hormone  technology  after  licensing  it  from  A/F  Protein, 
AquaBounty’s original parent company. However, as of 2000, both companies decided to 
abandon their research in the wake of controversy surrounding genetically engineered 
foods.
62 Authorities in both Chile and Norway rejected transgenic salmon out of fear of 
market  loss.
63  However,  despite  both  regulatory  and  public  opposition,  many  other 
commercial  fish  farming  companies  have  continued  to  conduct  genetic  research  on 
roughly  three  dozen  species  of  fish  worldwide,  including  other  salmonids  and 
economically important fish such as catfish and tilapia.
64 Many hope to eventually obtain 
market approval for their own genetically engineered fish.  
AquaBounty describes itself as a “biotechnology company focused on improving 
productivity  in  commercial  aquaculture”  to  meet  global  consumer  demand  for  high-
qualify seafood.
65 Its first targeted commercial product is the AquAdvantage salmon, 
which grows twice as fast as commercially raised salmon.
66 After approval by the FDA, it 
would expect the fish to be available in supermarkets within two to three years.
67 The fish 
would reach harvestable size in approximately 200 days, as opposed to the current 350 
days required by the domesticated Atlantic salmon currently raised on fish farms, and the 
700 days required by wild salmon.
68 Even though the AquAdvantage salmon grow faster 
and  reach  mature  size  earlier,  they  are  ultimately  not  larger  than  standard  salmon.
69 
AquaBounty’s  hybrid-fish  was  developed  using  the  combination  of  modern  DNA 
                                                 
62 Reichhardt supra note 47 at 10.  
63 Rebecca M. Bratspies, Farming the Genetically Modified Seas – The Perils and Promise of Transgenic 
Salmon, 62 AM. FISHERIES SOC’Y SYMP. 1, 14 (2008). 
64 Id. 
65 AquaBounty Technologies, The Company supra note 58. 
66 AquaBounty Technologies, AquAdvantage® Fish, http://aquabounty.com/products/ aquadvantage-
295.aspx (last visited April 25, 2011).  
67 Andrew Pollack, Modified Salmon is Safe, F.D.A. Says, N.Y. TIMES, Sept. 3, 2010. 
68 Fox supra note 41 at 1141. 
69 Id.   - 12 -   
procedures, including (1) gene and protein identification and analysis, (2) regulation of 
gene  expression,  (3)  receptor  identification  and  blocking  technologies  and  (4) 
transgenesis.
70  Using  the  same  DNA  technology,  the  company  is  also  developing 
equivalent tilapia and trout versions of its fast growing fish. The AquAdvantage salmon 
contains a growth hormone gene from the Pacific Chinook salmon that is kept active by a 
genetic on-switch obtained from a different fish, the ocean pout.
71 The ocean pout uses 
this promoter gene to regulate activity of its antifreeze protein gene, allowing it to survive 
the frigid water temperatures of New England and Atlantic Canada and grow year-round. 
By contrast, normal salmon only produce growth hormone in the spring and summer. The 
addition of the pout’s promoter gene to the modified AquAdvantage salmon’s genome 
ensures that the Chinook growth hormone is produced year-round, causing the salmon to 
grow twice as fast as a normal Atlantic salmon.
72 Because the AquAdvantage salmon 
grows much faster, AquaBounty expects a 20% efficiency gain in the amount of feed 
needed to bring the salmon to a harvestable size.
73 
In  AquaBounty’s  proposed  approach,  the  shock  or  heat  treatment  techniques 
described previously would be combined with another technique that allows for turning 
female salmon into male-like progenitors. Taking fertile genetically modified females 
and subjecting them to male sex hormone treatments converts them to sperm-producing 
“reverse males.” Because these fish are originally females, they are only able to produce 
female offspring when re-bred with the eggs of another female. The fertilized eggs are 
                                                 
70 AquaBounty Technologies, Our Technology, http://aquabounty.com/technology/ technology-296.aspx 
(last visited April 25, 2011) 
71 Stokstad supra note 52 at 1798 – 1799. 
72 Pollack, Modified Salmon is Safe, supra note 67. 
73 Stokstad supra note 52 at 1798.   - 13 -   
then pressure or heat treated, resulting in infertile adult female fish.
74 AquaBounty would 
retain a breeding stock on Prince Edward Island to produce an entire infertile female 
offspring stock produced solely for food production. Eggs for the production stock would 
be transported and hatched at an inland facility in Panama where the resulting fish would 
grown and ultimately be harvested and commercialized.
75 However, shocking salmon 
eggs to render them infertile is not entirely perfect and some scientists are concerned by 
the variability of results observed between batches.
76 AquaBounty’s most recent data 
claims that it is able to consistently achieve 99.8% infertility, with variability between 
batches ranging from 98.9% to 100%.
77 
  AquaBounty claims that its fish improves the economics of inland fish farming 
operations  through  reduced  growth  cycles.  The  company  claims  that  such  improved 
economics  eliminate  the  need  for  ocean  pens,  thereby  avoiding  the  problems  they 
generate.
78 Traditional ocean pens used for the commercial farming of fish are associated 
with environmental pollution resulting from fish dejections, and escape and interbreeding 
of farmed fish with wild populations. However, few commercial fish farming operations 
build inland systems because they generally increase the cost of raising fish by 40%.
79 
The advantages of using AquAdvantage salmon would need to be sufficient to justify 
these additional costs, but Aqua Bounty remains undeterred. The company believes that 
the  growing  demand  for  seafood,  the  ecological  damages  already  caused  by  coastal 
                                                 
74 Reichhardt supra note 47 at 11. 
75 Fox supra note 41 at 1142. 
76 Reichhardt supra note 47 at 11 (quoting Anne Kapuscinki, specialist in biotechnology and aquaculture at 
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aquaculture, and the limited number of remaining sites for further expansion of coastal 
aquaculture  will  all  push  the  industry  inland.  Given  these  constraints,  AquaBounty 
believes  that  using  the  AquAdvantage  salmon  will  allow  the  industry  to  remain 
competitive.
80  
3  Regulation of Transgenic Animals 
3.1  Commercialization Status of Genetically Engineered 
Animals 
 
There are few genetically engineered animals currently commercially sold in the 
United States, and none are sold for food applications. AquaBounty itself has been trying 
to obtain market approval for the AquAdvantage salmon for over a decade. Many other 
companies  also  seeking  to  commercialize  genetically  engineering  animals  for  food 
production  await  with  anticipation  the  outcome  of  AquaBounty’s  application.  The 
decision will set an important regulatory precedent and will have major implications for 
the future of the United States’ biotechnology sector. 
The genetically engineered animals currently sold in the United States are mostly 
laboratory animals used for medical research as well as the aquarium zebra fish sold 
under the trademark name GloFish. The GloFish went on sale in the United States on 
January 5, 2004 and is genetically engineered to glow in the dark,
81 but the FDA declined 
to exercise jurisdiction on the basis that “[b]ecause tropical aquarium fish are not used for 
food  purposes,  they  pose  no  threat  to  the  food  supply.”
82  Research  in  genetically 
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engineered animals is active in many different countries and is focused on efforts to 
improve  the  environmental  footprints  of  husbandry  animals,  improve  the  production 
efficiency of animal-derived food and the quality of animal-derived food, and produce 
human pharmaceuticals using animals. The FDA expects many of these products to reach 
markets  within  the  coming  decade.
83  Among  others,  these  include  the  University  of 
Guelph’s yet to be commercialized Enviropig, a pig engineered to digest phytic acid and 
thereby reduce both the need for phosphorus supplements in the animal’s diet and the 
amount of unabsorbed phosphorus in the pig’s manure, a common source of pig farming 
pollution.
84 New Zealand researchers are using rDNA technology to improve the cheese-
making  quality  of  milk  by  increasing  the  amount  of  casein  protein  found  in  milk 
produced  by  genetically  engineered  dairy  cows.
85  The  Roslin  Institute  in  Scotland  is 
developing genetically engineered chickens that produce pharmaceuticals in their eggs
86 
as well as others that do not transmit bird flu to other chickens and thereby prevent the 
outbreak of bird flu within domestic poultry stocks.
87, 88 
                                                                                                                                                
neeredAnimals/ucm161437.htm. For a detailed analysis of why the FDA chose not to regulate GloFish see 
Bratspies supra note 81.  
83 Genetically Engineered Animals, General Q&A , U.S. Food & Drug Admin. (1 Jul. 2009), available at 
http://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/GeneticEngineering/ 
GeneticallyEngineeredAnimals/ucm113605.htm. 
84 University of Guelph, Enviropig, http://www.uoguelph.ca/enviropig/ (last visited May 10, 2011). Most 
cereal grains, including common pig feed ingredients corn and soybean, contain 50 to 75% of their 
phosphorus in the form of phytic acid, which cannot be digested by normal pigs. 
85 BBC News, GM Cheese from Cow Clones, BBC, Jan. 27, 2003, available at 
http://news.bbc.co.uk/2/hi/sci/tech/2696725.stm. 
86 Genetically Engineered Animals, General Q&A supra note 83. 
87 Roslin Institute, GM Chickens, http://www.roslin.ed.ac.uk/public-interest/gm-chickens/ (last visited May 
10, 2011). 
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3.2  Regulation under the Federal Food, Drug and Cosmetic Act 
3.2.1  General Requirements 
 
Genetically  engineered  animals  are  regulated  by  the  Center  for  Veterinary 
Medicine
89 under the Federal Food Drug and Cosmetic Act (FFDCA). The FDA clarified 
and  asserted  its  jurisdiction  over  genetically  engineered  animals  in  its  Guidance  for 
Industry 187.
90 The FDA asserted jurisdiction over genetically engineered animals under 
the  New  Animal  Drug  provisions  of  the  FFDCA  on  the  grounds  that  the  genetic 
modification  of  such  animals  affects  their  “structure  and  function”  in  a  way  that  is 
analogous to how veterinary drugs affects them.
91 Under this interpretation, given that it 
modifies the traits of the genetically engineering animal, the FDA considers the rDNA 
construct, the genetic material that is inserted into the DNA of the original animal, to 
qualify as a “drug.” The FDA extends its jurisdiction to the entire lineage of genetically 
engineered animals that contain the DNA modification, and includes animals that inherit 
the rDNA construct as a result of breeding genetically engineered animals with non-
genetically engineered animals.
92 The FDA has chosen to regulate genetically engineered 
animals differently than genetically engineered plants on the basis that it believes that 
unlike plants, animals can much more easily transmit diseases to humans, a phenomenon 
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known scientifically as zoonotic disease transmission. Animals can also be the source of 
novel viral diseases that eventually affect humans. As a result, the FDA is concerned that 
genetic  engineering  of  animals  might  enhance  these  risks  of  disease  formation  and 
transmission.
93 
  Guidance  187  recommends  that  sponsors  of  genetically  engineering  animals 
provide seven core types of data to meet the information requirements of a NADA. This 
includes (1) the product definition, a broad characterization of the genetically engineered 
animal and associated claims about its properties; (2) the molecular characterization of 
the  construct,  a  description  of  the  rDNA  construct  and  how  it  is  assembled;  (3)  the 
molecular characterization of the genetically engineered animal lineage, a description of 
the rDNA construct genetic insertion method as well as an analysis of its stability over 
time;  (4)  phenotypic  characterization  of  the  genetically  engineered  animal,  a 
comprehensive data set on the health and characteristics of the genetically engineered 
animal;
94 (5) durability plan, an explanation on how the sponsor plans to demonstrate that 
the genetic modification will remain stable between animal generations and continue to 
have the same effect; (6) environmental and food / feed safety, an assessment of any 
environmental impacts, and for any animals intended to be used as food for humans or 
other animals, an assessment of whether or not such genetically engineered animals will 
                                                 
93 Genetically Engineered Animals, General Q&A supra note 83. 
94 To determine the potential adverse health affects of the rDNA construct on genetically engineered 
animals, the FDA recommends that sponsors provide veterinary and treatment records, and data on growth 
rates, reproductive function, and behavior. Physiological data recommendations include clinical chemistry, 
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be safe to eat; and (7) claim validation, a demonstration that the genetically engineered 
animal does actually fulfill the claims made by the sponsor.
95  
As most methods to introduce new rDNA constructs into the genetic material of 
an animal cannot control the exact site where the construct will be inserted, the FDA 
considers  each  animal  lineage  derived  from  separate  insertions  as  meriting  its  own 
NADA.
96 The FDA’s position is based on the fact that the location of an inserted rDNA 
construct can affect both the health of the animal and the level of expression of the 
construct.
97 Because genetically engineered animals used for commercial purposes are 
likely to be the descendants of the initial genetically engineered animals used for the 
approval, the FDA also requires that sponsors demonstrate that “the construct and / or 
phenotype  are  stability  maintained  in  a  representative  sample  of  animals”  involving 
multiple generations.
98 
The  FDA  clearly  states  that  Guidance  187  represents  the  agency’s  “current 
thinking” on the topic and “does not create or confer any rights for or on any person and 
does  not  operate  to  bind  the  FDA  or  the  public”  and  envisions  the  possibility  of 
alternative approaches to assessing the risks and characteristics of a genetically modified 
animal.
99 Guidance 187 does not diminish the fact that because genetically engineered 
fish are akin to a new animal drug, statutes and regulation require them to have met any 
and all New Animal Drug Application (NADA) requirements prior to marketing. No new 
requirements  are  imposed,  and  the  Guidance  is  meant  to  help  sponsors  provide  the 
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necessary NADA information in order for the FDA to find that their product is safe and 
effective.
100  
Guidance 187 was developed in response to the lack of dedicated laws for the 
development of novel foods and drugs derived from genetically engineered animals, and 
the  regulatory  uncertainty  this  created  for  many  biotechnology  companies  and 
investors.
101 When Guidance 187 was originally drafted, few of the public comments 
were  critical  of  the  agency’s  interpretation  of  its  statutory  authority  or  the 
recommendations for data submission.
102 However, many commentators were critical of 
the  FDA’s  choice  of  the  NADA  process  because,  as  most  drug  applications  are 
confidential, there is limited opportunity for public comment and participation, and not 
all  data  is  disclosed.
103  In  addition,  many  believe  that  the  NADA  framework  is 
inadequate and that a dedicated novel food application process is necessary,
104 with some 
people suggesting that it is like “jamming a square peg in a round hole.”
105  
 Given the novelty of genetically engineered animals for human consumption, the 
relative lack of regulatory experience, and the high level of public interest in the use of 
genetically modified animals, the FDA modified Guidance 187 to include an intent, but 
no  formal  commitment,  to  hold  public  advisory  meetings  prior  to  approving  any 
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genetically engineered animal.
106 In the case of AquAdvantage salmon, the decision to 
hold a public hearing was the result of Aquabounty’s agreement to do so. The FDA’s 
Center for Veterinary Medicine also deemed it necessary to add additional Committee 
members on an ad hoc basis to provide missing expertise in “molecular biology and the 
production of genetically engineered animals,” as well as “issues associated with Atlantic 
salmon, and salmonids in general.”
107  
3.2.2  Health and Safety Issues Surrounding the AquAdvantage 
Salmon 
 
  In the summer of 2010, the FDA announced that after over a decade of attempting 
to obtain the authorization to market its AquAdvantage salmon, AquaBounty had now 
provided sufficient information to the agency for it to make a decision. In documents 
released for the public hearing held by the Veterinary Medicine Advisory Committee on 
September 19 – 20, 2010, the FDA stated that the AquAdvantage salmon did indeed grow 
faster and resulted in food that is “as safe as food from conventional Atlantic salmon.”
108 
Critics  however  pointed  out  that  the  study  set  a  precedent  with  a  low  bar  for  other 
genetically engineered animals and focused on the fact that the data provided did not 
fully comply with NADA requirements.
109  
One concern was the fact that the engineered salmon had slightly higher levels of 
insulinlike growth factor 1 (IGF1). Studies suggest that high blood levels of this hormone 
may be associated with greater cancer risk, but the role of IGF1 content in food on these 
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levels remains unclear.110 However, after a careful study, the FDA concluded that even if 
people consumed large volumes of AquAdvantage salmon, this would be unlikely to have 
an effect on their IGF1 levels.
111 There were however concerns surrounding the adequacy 
of the data used to conduct allergen studies, with several critics pointing out that the 
study was based on samples taken from only twelve fish in total.
112 
The FDA study concluded by requiring that AquaBounty develop a post-approval 
monitoring  plan  in  line  with  what  is  suggested  in  Guidance  187.  The  FDA  notably 
requested that a durability plan be set up and maintained to monitor the genetic make-up 
and characteristics of the genetically engineered fish, in part in response to concerns over 
malformations on the jaws of some fish and under-counting of deformed fish through 
normal culling procedures conducted during fish farming.
113  
  There  has  been  growing  opposition  from  Congressional  representatives  to  the 
approval of the AquAdvantage salmon and the FDA has yet to make a final decision on 
AquaBounty’s NADA. The FDA has also clearly stated that it will not weigh in on the 
debate over ethical issues surrounding biotechnology. While it does consider the impact 
of new drugs, and thus rDNA constructs, on the health of animals, it does not consider its 
role to be to decide whether or not genetic engineering of animals for food should be 
allowed as a matter of policy.
114 
                                                 
110 Pollack, Modified Salmon is Safe, supra note 67. See also Stokstad supra note 52 at 1799. 
111 Briefing Packet supra note 108 at 69 – 77. 
112 Smith supra note 104 at 204 – 205; Pollack, Modified Salmon is Safe, supra note 67. 
113 Briefing Packet supra note 108 at 48 – 61. 
114 Genetically Engineered Animals, General Q&A supra note 83.   - 22 -   
3.2.3  Labeling Requirements 
 
Section 514.1(b)(3) of Code of Federal Regulations requires that a NADA include 
three copies of each label that will be used for the new animal drug. However, this is 
different  from  labeling  requirements  for  the  actual  food  derived  from  the  genetically 
engineered animal. The FDA has so far indicated its intent to apply the same labeling 
requirements to food derived from genetically engineered animals that it applies to food 
derived  from  non-genetically  engineered  animals  and  genetically  engineered  plants. 
Under its interpretation of §403(j) of the FFDCA, unless there is material information 
pertinent  to  the  food  derived  from  genetically  engineered  animals,  there  will  be  no 
specific labeling requirements.
115 In other words, if the food derived from a genetically 
engineered animal is no different than food derived from its non-genetically modified 
counterparty, the principle of equivalency prevails and no further labeling is required. If 
however food derived from a genetically engineered animal has different nutritional or 
other properties that may affect the structure and function of a consumer of such food, 
then labeling is required.
116 
Given  the  unprecedented  nature  of  the  first  application  to  commercialize  a 
genetically  engineered  animal  for  human  consumption  and  the  considerable  public 
interest  in  the  matter,  the  FDA  chose  to  hold  a  public  hearing  on  the  labeling  of 
genetically  engineered  foods  the  day  after  it  held  a  public  hearing  on  AquaBounty’s 
NADA.
117 While the FDA decided to hold a public hearing “to educate the public about 
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[its]  food  labeling  principles  and  how  they  apply  to  foods  derived  from  [genetically 
engineered] animals,” it also sought comments on its current approach to the labeling of 
food derived from AquAdvantage salmon.
118 It specifically sought comments on whether 
there were “any material differences – including differences in the composition of the 
food or its nutritional, function or organoleptic properties – that justif[ied] naming or 
labeling  food  from  [the  AquAdvantage  salmon]  differently  from  food  from  its 
conventional counterparts.”
119 This further suggests that the FDA intends to apply the 
same approach used for foods derived from genetically engineered plants, namely that the 
use  of  recombinant  DNA  techniques  is  not  considered  material  information  under 
§201(n) of the FFDCA. Similarly to its approach to genetically engineered plants, the 
FDA  likely  considers  that  the  genetic  manipulation  of  animal  DNA  is  simply  an 
extension  of  the  natural  selective  crossbreeding  processes  that  humans  have  used  for 
many years.
120 It is however noteworthy to contrast how the FDA considers genetically 
engineered animals potentially more dangerous to humans than genetically engineered 
plants when justifying its jurisdiction and extension of NADA requirements to sponsors, 
but retains a stronger notion of equivalency when it comes to labeling foods once they 
have passed threshold requirements of safety for both human and animal consumption.  
Perhaps  demonstrating  the  limit  of  using  the  existing  NADA  framework  for 
genetically  engineering  animals,  the  FDA  seems  to  consider  that  until  they  reach 
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commercial  growing  facilities,  genetically  engineered  salmon  retain  more  drug-like 
characteristics  than  food-like  characteristics,  or  at  least  are  characterized  as  animals 
“treated”  with  drugs,  where  “drugs”  are  the  rDNA  construct  that  the  growing  stock 
contain. Indeed, regardless of whether or not it will decide to require labeling of the 
actual  food  derived  from  the  AquAdvantage  salmon,  the  FDA  has  stated  that  any 
approval will require a label that identifies the different types of rDNA constructs that 
accompany any eggs and young fish transiting from breeders to growers.
121 However, 
once the fish are commercialized in supermarkets, the FDA’s proposed approach will 
consider the genetically engineered fish to have become purely “food.” While perhaps the 
use  of  the  NADA  framework  is  merely  a  continuation  of  the  FDA’s  precautionary 
approach to ensuring the safety of the food supply in the United States and a testament to 
the agency’s ingenuity in using existing law in the face of rapidly evolving technology, it 
also suggests that a dedicated novel food regulatory approach for genetically engineered 
animals may be warranted.   
3.3  Environmental Regulation 
 
Applications  for  approval  of  genetically  engineered  animals  are  subject  to 
environmental review under the National Environmental Policy Act (NEPA), through 
regulations implemented by the Council on Environmental Quality
122 and the FDA.
123 
Under  the  extraordinary  circumstances  that  would  justify  at  least  an  environmental 
assessment for an action that would usually be categorically excluded from scrutiny, the 
FDA  may  consider  the  “harm  to  the  environment  to  include  not  only  toxicity  to 
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environmental  organisms  but  also  environmental  effects  other  than  toxicity,  such  as 
lasting effects on ecological community dynamics.”
124 Under Guidance 187, when the 
FDA exercises its enforcement discretion over a new genetically engineered animal, no 
additional  NEPA  action  is  required  on  the  basis  that  the  FDA  includes  NEPA 
requirements in its own review.
125 In its approval process, at a basic level, the FDA 
considers (1) whether the genetically engineered animal poses any threats to humans, 
animals  or  the  environment;  (2)  whether,  in  the  event  of  a  release,  the  genetically 
engineered  animal  poses  any  more  environmental  threat  than  the  non-genetically 
engineered equivalent; (3) whether the disposal of genetically engineered animals poses 
any threats to humans, animals or the environment; and (4) whether any other safety 
issues  remain  unaddressed  by  the  sponsor.
126  At  minima,  a  sponsor  must  prepare  an 
environmental assessment (EA) to demonstrate whether or not the genetically engineered 
animal will have no significant impact on the environment. No further action on behalf of 
the sponsor is required in case of a finding of no significant impact (FONSI).
127 Critics of 
Guidance  187  claim  that  using  the  NADA  approach  does  not  fully  account  for 
environmental consequences of genetically engineered animals.
128 Questioning whether 
NADA is indeed the right approach may be particularly poignant given the fact that wild 
Atlantic salmon is currently listed as an endangered species.
129 
There are major concerns about the potential escape of AquaAdvantage salmon 
into the wild. To mitigate this risk, AquaBounty proposes that the commercially raised 
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salmon  will  be  entirely  female  and  infertile,  and  grown  in  physically  contained 
production systems. This is actually a reversal from AquaBounty’s original proposal to 
consider growing fish in ocean cage settings, where the potential escape into the wild is 
much higher.
130 Although not acknowledged publicly, it is perhaps because AquaBounty 
is unable to guarantee with absolute certainty that all the eggs it will produce at its Prince 
Edward Island facilities will be infertile that it chose to propose to grow the fish to 
commercial harvesting size only at its Panama inland facility. The FDA agrees with this 
approach, stating that it believes that the chance of ecological disruption or escape is 
small.
131  
AquaBounty’s application and pending approval by the FDA were later mired in 
controversy  surrounding  the  fact  that  the  agency  had  supposedly  not  sufficiently 
consulted with the Fish and Wild Services and other expert agencies, and that a full 
Environmental  Impact  Statement  was  required  to  assess  the  potential  impact  of  the 
AquAdvantage  salmon  on  the  endangered  Atlantic  salmon.  In  particular,  there  was 
concern  that  genetically  engineered  salmon  might  escape  the  Prince  Edward  Island 
breeding facility and could potentially make their way to the Atlantic ocean from there.
132 
Critics  accused  the  FDA  of  “applaud[ing]  the  company’s  choice  of  land-based 
containment as responsible [while] it never revealed that it is illegal in the U.S. to grow 
genetically engineered salmon in open-water net pens.”
133 Under §7 of the Endangered 
Species Act, federal agencies are required to consult with expert agencies when an action 
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may impact a protected species and expert agencies are required to draft a Biological 
Opinion on how to protect the endangered species in question in relation to the proposed 
action. While the FDA claimed that preliminary discussions were held with both the Fish 
and Wildlife Services and the National Marine Fish Services, no follow-up discussion 
took place. It was also alleged that as of October 2010, AquaBounty was still considering 
rearing fish in Atlantic waters and had approached the Fish and Wildlife Services in 
regards  to  this.
134  By  contrast,  in  2001,  in  regards  to  pending  ocean-based  fish  farm 
permit applications, the Fish and Wildlife Services, and the National Marine Fisheries 
Services, issued a Biological Opinion to the Environmental Protection Agency expressing 
their concern that transgenic salmon would adversely affect wild Atlantic salmon. In their 
Opinion, both agencies banned the use of reproductively viable transgenic salmon on all 
ocean-based fish farms.
135 The FDA was later accused of failing to disclose the existence 
of this Biological Opinion at the public hearings it held in September 2010 in regards to 
the  AquaBounty  NADA.
136  In  the  FDA’s  defense,  it  clearly  stated  that  the  current 
NADA, if approved, would only be valid for exclusive rearing of the commercial fish in 
AquaBounty’s Panama facility. Raising the fish anywhere else would require another 
application to the FDA, including any application by a third party to purchase fertilized 
eggs from the Prince Edward Island facility for growing and commercialization at any 
other location.
137  On the other hand, AquaBounty’s official position remains unclear, and 
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its website still suggests that the AquAvantage salmon is entirely infertile and poses no 
threat  of  interbreeding  with  native  populations  when  they  escape,  despite  its 
Environmental Assessment that states the contrary.
138, 
139 
4  Conclusion 
 
It is clear from the ongoing debate and regulatory approval of the AquAdvantage 
salmon that the choice to adopt the NADA framework to analyze the potential risks of 
genetically  engineered  animals  remains  questioned  by  several  parties.  Legislation  is 
struggling to keep up with the rapid pace of innovation in the sector. Given the lack of 
comprehensive and dedicated legislation on the use of genetically engineered animals for 
food production, the FDA has been forced to use existing regulatory frameworks to the 
best of its capabilities. Above all, the core criticism that can be laid on the use of the 
NADA  framework  is  its  poor  suitability  to  assess  the  idiosyncratic  risks  that 
AquAdvantage  salmon  pose  to  the  already  endangered  Atlantic  salmon.  Perhaps  an 
application by a genetically engineered animal less likely to stir environmental concerns, 
such as the Enviropig, may have provided for a more ordinate testing of the NADA 
framework.  Despite  some  reservations  about  the  quality  of  the  data  submitted  in 
AquaBounty’s  application,  the  NADA  at  least  has  the  merit  of  focusing  most  of  its 
analysis on the potential human health effects of genetically engineered animals used as 
food. It is perhaps still too early to tell whether or not genetically engineered animals 
merit an entirely different approach to risk assessment given the still relative infancy of 
the science and its applications, but the AquAdvantage salmon case suggests that so far, 
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the FDA has failed to convince both the industry and the public that is has finally found 
the right approach to regulating genetically engineered animals used for food. 
Conversely, in the midst of scientific uncertainty, it is not surprising that exactly 
how consumers feel about genetically engineered animals remains unclear. Even though 
genetically engineered plants are now found in huge numbers in the United States food 
supply,  debate  about  their  merits  and  potential  risks  continues.  In  addition,  perhaps 
echoing  the  FDA’s  concern  about  more  similarities  between  humans  and  animals  in 
comparison to plants, and thus potentially higher risks of disease transmittal, consumers 
seem more wary about genetically engineered animals.
140 On the other hand, other polls 
suggest that consumers may be more willing to accept genetically engineered animals 
that provide environmental and nutritional benefits.
141 It is therefore not surprising that 
AquaBounty’s  application  has  become  the  focal  point  of  debate  over  genetically 
engineered  animals  used  for  food  production,  and  genetic  engineering  of  animals  in 
general.  
Both  the  House  of  Representatives  and  the  Senate  have  advanced  bipartisan 
regulatory  proposals  to  prohibit  the  approval  of  genetically  engineered  fish  for  food 
production by deeming them unsafe under the current FFDCA,
142 as well as a bill to 
separately require labeling of such foods should the FDA approve them.
143 Recently re-
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introduced in the 112th Congress,
144 the bills were originally proposed following a letter 
by  30  House  members  and  13  senators  to  the  Obama  administration  questioning  the 
FDA’s review of the AquaBounty application and even asking the administration to ban 
the  commercialization  of  the  genetically  engineered  salmon.
145  No  decision  on  the 
AquAdvantage application has yet to be announced, and neither AquaBounty nor the 
FDA have provided any further information since the September 2010 public hearings. 
AquaBounty has only stated its intent to continue working with the FDA and address any 
issues  raised  should  the  agency  reject  its  NADA.
146  A  rejection  of  AquaBounty’s 
application will continue to put into question the FDA’s use of the NADA framework and 
may  push  the  biotechnology  industry  to  request  Congress  to  enact  comprehensive 
legislation  dedicated  to  genetically  engineered  animals.  But  on  the  other  hand,  an 
approval by the FDA is unlikely to silence critics of the use of the NADA framework, as 
well  as  unlikely  to  silence  genetic  engineering  opponents  in  general.  The  legislative 
proposals put forth so far are merely stopgap measures focused on the AquaAdvantage 
salmon. No comprehensive legislation, with the potential to more firmly settle the issue 
favorably or unfavorably, has been proposed. For both consumers and the biotechnology 
industry, the outlook over the future of genetically engineered animals raised for food 
production continues to remain fraught with uncertainty. 
                                                 
144 H.R. 521, 112th Cong. (2011); S. 230, 112th Cong. (2011). H.R. 520, 112th Cong. (2011); S. 229, 112th 
Cong. (2011).  
145 Statement by Wenonah Hauter, Senator Introduces Common-sense Federal Bills to Address 
Controversial Genetically Engineered Salmon, Food & Water Watch (Nov. 18, 2010), available at 
http://www.foodandwaterwatch.org/pressreleases/senator-introduces-common-sense-federal-bills-to-
address-controversial-genetically-engineered-salmon/ 
146 Stuart Hirsch, Super Salmon? AquAdvantage has Become a Lightning Road for Transgenic Critics, 
SEAFOOD BUS. MAG., Dec. 1, 2010, available at http://www.seafoodbusiness.com/articledetail.aspx?id 
=4295000307. 